162012-28-4

Basic information

• Product Name: 4-(4-(methylthio)phenyl)furan-2(5H)-one
• Synonyms: 4-(4-(methylthio)phenyl)furan-2(5H)-one
• CAS NO: 162012-28-4
• Molecular Weight: 206.265
• Mol File: 162012-28-4.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-(methylthio)phenyl)furan-2(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(methylthio)phenyl)furan-2(5H)-one(162012-28-4)
• EPA Substance Registry System: 4-(4-(methylthio)phenyl)furan-2(5H)-one(162012-28-4)

Safety Data

• Hazardous Substances Data: 162012-28-4(Hazardous Substances Data)

Upstream product

• 329328-49-6 3-bromo-4-(4'-methylthiophenyl)-5H-furan-2-one 
• 56634-50-5 4-bromo-5H-furan-2-one 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 
• 1174747-84-2 C₁₅H₂₁O₆PS 

Downstream Products

• 213764-00-2 2-benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone 

Relevant articles and documents

Novel and efficient route for the synthesis of 4-Aryl-substituted 2(5H)-furanones

4-Aryl-substituted 2(5H)-furanones were prepared by reaction of diethylphosphono acetic acid and phenacyl bromides, followed by an intramolecular Horner-Emmons-type cyclization. Both the reactions were carried out in situ to give the desired 4-aryl substituted 2(5H)-furanone derivatives.

Pyridazinones as selective cyclooxygenase-2 inhibitors

Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.

Selective synthesis of unsymmetrical 3,4-disubstituted and 4-substituted 2(5H)-furanones

Easily available 3,4-dibromo-2(5H)-furanone undergoes regioselective palladium-catalyzed reaction with aryl(trialkyl)stannanes to give the corresponding 4-aryl-3-bromo-2(5H)-furanones in satisfactory yields. These monobromo derivatives have proven to be useful precursors to unsymmetrical 3,4-diaryl-2(5H)-furanones, 4-aryl-3-methyl-2(5H)-furanones and 4-aryl-2(5H)-furanones.

Compositions for a once day treatment of cyclooxygenase-2 mediated diseases

PCT No. PCT/US97/08041 Sec. 371 Date Mar. 8, 1999 Sec. 102(e) Date Mar. 8, 1999 PCT Filed May 13, 1997 PCT Pub. No. WO97/44028 PCT Pub. Date Nov. 27, 1997This application relates to a method of treating a disease susceptible to treatment with a non-steroidal anti-inflammatory drug by administering to a patient once daily an effective amount of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: STR1

Method of preventing bone loss

The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. STR1 The invention also encompasses certain pharmaceutical compositions for the purposes described above.